Online inquiry

IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ751MR)

This product GTTS-WQ751MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ751MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3155MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ11636MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ1693MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ15511MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ136MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ1512MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-011
GTTS-WQ4244MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ3271MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ART621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW